Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micro-encapsulated Hepatocytes for Adult Liver Failure
NCT05727722Phase 1Recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of micro-encapsulated hepatocytes in chronic liver failure and acute-on-chronic liver failure (ACLF) (4 cohorts), sponsored by Renji Hospital. Primary endpoints: Incidence of Adverse events at 60 days and Maximum Tolerated Dose at 60 days. Started Mar 2024; status: recruiting.
02
Drugs
micro-encapsulated hepatocytes
03
Conditions
chronic liver failureacute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT05727722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727722.